MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

10.98 -0.72

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

10.72

Максимум

11.2

Ключови измерители

By Trading Economics

Приходи

915K

-11M

Служители

42

EBITDA

106K

-12M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+157.69% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

201M

928M

Предишно отваряне

11.7

Предишно затваряне

10.98

Настроения в новините

By Acuity

17%

83%

27 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.07.2025 г., 23:34 ч. UTC

Придобивния, сливания и поглъщания

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17.07.2025 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17.07.2025 г., 21:04 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17.07.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17.07.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17.07.2025 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17.07.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17.07.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17.07.2025 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17.07.2025 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17.07.2025 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17.07.2025 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17.07.2025 г., 22:30 ч. UTC

Пазарно говорене
Печалби

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17.07.2025 г., 22:20 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

17.07.2025 г., 22:20 ч. UTC

Пазарно говорене
Печалби

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17.07.2025 г., 22:04 ч. UTC

Пазарно говорене
Печалби

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17.07.2025 г., 22:03 ч. UTC

Придобивния, сливания и поглъщания

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17.07.2025 г., 21:58 ч. UTC

Пазарно говорене
Печалби

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17.07.2025 г., 21:57 ч. UTC

Печалби

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17.07.2025 г., 21:47 ч. UTC

Печалби

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17.07.2025 г., 21:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.07.2025 г., 21:45 ч. UTC

Пазарно говорене

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17.07.2025 г., 21:38 ч. UTC

Придобивния, сливания и поглъщания

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17.07.2025 г., 21:22 ч. UTC

Придобивния, сливания и поглъщания

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17.07.2025 г., 21:05 ч. UTC

Печалби

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17.07.2025 г., 21:04 ч. UTC

Придобивния, сливания и поглъщания

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17.07.2025 г., 21:02 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17.07.2025 г., 20:59 ч. UTC

Придобивния, сливания и поглъщания

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

17.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

157.69% нагоре

12-месечна прогноза

Среден 28.5 USD  157.69%

Висок 42 USD

Нисък 15 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

2

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

27 / 376 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.